South Korea Bioceramics Market Overview, 2031

Key Insights

• The South Korean bioceramics market operates within a healthcare environment defined by the country's official transition to a "super-aged society" in 2024, where over 20% of the population is aged 65 or older. Korea's total population was estimated at 51.7 million in 2025, with approximately 10.3 million people aged 65 and above, representing one of the fastest demographic transitions globally. According to the Health Insurance Review and Assessment Service (HIRA), approximately 4.3 million people sought medical treatment for osteoarthritis in 2023, with approximately 90% being in their 50s or older. Osteoarthritis is the most common age-related disease in Korea, with radiographic knee osteoarthritis prevalence of 14.9% among adults aged 40 and above. Among Koreans aged 50 and older, knee osteoarthritis prevalence reaches 33.4% (Kellgren-Lawrence grade ≥2), with significantly higher rates in women at 43% compared to 20.1% in men. The prevalence of osteoarthritis among those aged 65 and older was 30.2% between 2017 and 2021, underscoring the substantial and growing clinical burden. Total knee replacement surgeries in South Korea rose from 64,515 in 2010 to 106,149 in 2024, reflecting a 64.5% increase over 14 years.
• South Korea's healthcare delivery model for Bioceramics devices is characterized by one of the world's most comprehensive and accessible national health insurance systems, operated by the National Health Insurance Service (NHIS), which provides universal coverage to the entire population. The NHIS covers approximately 97% of the population, with the remaining 3% covered by Medical Aid programs for low-income individuals. The NHIS has progressively expanded dental coverage, with dentures added in 2012 and dental implants added in 2014 for older adults, with age eligibility gradually lowered to 65 years. The registry data has been instrumental in analyzing the epidemiology of hip and knee arthroplasties, with studies documenting that ceramic-on-ceramic bearings are used at an overwhelmingly high rate (81%) in Korea compared to other countries. The registry also tracks revision total knee arthroplasty following periprosthetic joint infection (RTKA-f-PJI), which increased by 57.6% between 2011 and 2019, with the total cost rising from $15.7 million to $19.6 million over the same period.
• Regulatory oversight for medical devices in South Korea is administered by the Ministry of Food and Drug Safety (MFDS) under the Medical Devices Act (MDA). Medical devices are classified into four risk categories (Class I to IV), with implantable Bioceramics devices typically classified as Class III or IV, requiring the most rigorous scientific review and MFDS approval. For Class II, III, and IV devices, manufacturers must submit a technical dossier that proves the safety and effectiveness of the product. Foreign manufacturers must appoint a Korean License Holder (KLH) to represent them. For implantable devices, a new legal framework has introduced post-market tracking requirements, reflecting South Korea's intent to encourage innovation while maintaining strict oversight of safety and quality. The Korean bioceramics market is characterized by the presence of both domestic manufacturers including Meta Biomed, Inobone, Biocera, and Hass Bio and international suppliers such as CeramTec, Zimmer Biomet, Stryker, and Straumann.

Market Outlook

• According to the research report, "South korea Bioceramics Market Outlook, 2031," published by Bonafide Research, the South Korea Bioceramics Market is expected to reach a market size of more than 190 Million by 2031.
• A defining characteristic of South Korea's bioceramics market is the country's position as one of the world's most rapidly aging societies, combined with a comprehensive national health insurance system that has progressively expanded access to joint replacement and dental implant procedures. The transition to a super-aged society where over 20% of the population is aged 65 or older has created unprecedented demand for age-related healthcare services. The prevalence of osteoarthritis increases dramatically with age, from 18.20% among the young-old (60–74 years) to 35.50% among the old-old (75 years and older). This demographic shift is driving sustained growth in joint replacement procedures, with TKA and RKA showing rapid increases of 407% and 267%, respectively, between 2001 and 2010. The Korean National Registry's comprehensive data on arthroplasty trends provides an unparalleled foundation for evidence-based clinical decision-making and implant surveillance.
• The market also reflects Korea's distinctive position as a global leader in ceramic bearing adoption for hip replacements. Registry data shows that ceramic-on-ceramic bearings are used at an overwhelmingly high rate (81%) in Korea compared to other countries. This exceptionally high adoption rate is attributable to various factors, including patient age, economic status, differences in the health insurance system between countries, and the reported complications associated with alternative bearing surfaces. The cementless biological fixation method is predominantly used, with cemented fixation selectively employed for a small portion of elderly osteoporotic patients. The predominance of ceramic bearings in Korea creates a substantial and sustained market for Bioceramics femoral heads and acetabular liners, with domestic manufacturers such as Kyocera (through its Korean operations) and international suppliers competing in this premium segment.
• Korea's dental bioceramics sector is characterized by the country's position as a global manufacturing powerhouse for dental implants. Dental implants represented the highest production performance in Korea's medical device industry at ₩2.81 trillion in 2024, with an average annual growth rate of 19.7% over the past five years. Dental implant fixtures were among the leading export products, with exports of dental implant fixtures increasing by 16.0% year-on-year. According to the Korea Health Industry Development Institute (KHIDI), dental implant exports are expected to reach $1.003 billion in 2025, a 12.7% increase from 2024's $890 million. The primary export markets for Korean dental implants include China, Russia, the United States, the Netherlands, and Türkiye. This robust export performance reflects the international competitiveness of Korean dental implant manufacturers and the growing global demand for zirconia-based ceramic implants. The Korean dental implant market is also supported by the NHIS's coverage of dental implants for older adults since 2014, which has expanded access to implant procedures.

Market Dynamics

Driver: Demographic transition to a super-aged society and the associated burden of osteoarthritis
South Korea's bioceramics market is fundamentally driven by the country's unprecedented demographic transition. Korea officially became a super-aged society in December 2024, with over 20% of the population aged 65 or older. The proportion of older adults is projected to continue increasing, making Korea one of the fastest-aging countries in the world. Osteoarthritis is the most common age-related disease affecting the elderly population, with approximately 4.3 million people seeking medical treatment for the condition in 2023. Among those aged 65 and older, the prevalence of osteoarthritis was 30.2% between 2017 and 2021. The prevalence of osteoarthritis increases from 18.20% among those aged 60-74 to 35.50% among those aged 75 and older. Knee osteoarthritis is the most prevalent form, with radiographic prevalence of 14.9% among adults aged 40 and above. Among Koreans aged 50 and older, knee osteoarthritis prevalence reaches 33.4% (Kellgren-Lawrence grade ≥2), with significantly higher rates in women at 43% compared to 20.1% in men. This massive clinical burden, combined with the universal health insurance coverage provided by the NHIS, is driving sustained growth in joint replacement procedures. Total knee replacement surgeries rose from 64,515 in 2010 to 106,149 in 2024. The number and rate of patients who underwent hip joint arthroplasty per 10,000 persons have been steadily increasing since 2007. The incidence rate of joint replacement surgery in patients with rheumatoid arthritis increased from 0.72% in 2010 to 4.03% in 2016.

Challenge: Rising burden of revision surgeries and periprosthetic joint infections
One of the principal challenges facing South Korea's bioceramics market is the increasing burden of revision surgeries and associated complications. The demand for TKA has increased worldwide owing to the extension of life expectancy; therefore, revision TKA following PJI (RTKA-f-PJI) is also expected to increase. Between 2011 and 2019, the total growth rate of RTKA-f-PJI was 57.6%, with the RTKA-f-PJI rate maintained at approximately 30%. The RTKA-f-PJI rate was higher in males than in females, and the number of RTKA-f-PJIs markedly increased in patients aged 70-79 years and ≥80 years. The total cost of RTKA-f-PJI increased from $15.7 million in 2011 to $19.6 million in 2019. The mean personal cost of RTKA-f-PJI was more than 4 times higher than that of RTKA-f-non-PJI. Given that RTKA-f-PJI is a complex procedure associated with higher complication rates and unsatisfactory functional outcomes, continuous efforts to reduce the incidence of PJI after TKA are necessary. The RTKA-f-PJI rates for early and late failures were 45% and 24.8%, respectively. Additionally, the market faces challenges related to the high cost of premium ceramic implants and the need to balance clinical effectiveness with cost-efficiency within the NHIS reimbursement framework.



Trend: Expansion of robotic-assisted joint replacement surgery and digital dentistry
South Korea is experiencing a significant shift toward technologically advanced orthopedic and dental care, supported by robotic-assisted surgical systems and digital health integration. Robotic artificial joint surgery is a method of precisely removing damaged joints and inserting artificial joints using robots like "navigation". Director Kim Jae-hyung stated, "Robot artificial joint surgery can be customized by accurately adjusting to the patient's... joint condition". The growing adoption of robotic-assisted surgery in Korean hospitals is driving demand for advanced Bioceramics components that offer superior precision and compatibility with robotic systems. In the dental sector, the adoption of CAD/CAM technology and digital dentistry workflows is accelerating, with Hass Bio offering CAD/CAM systems for dental restorations. The Korea International Medical & Hospital Equipment Show (KIMES) serves as a platform for showcasing these advanced technologies. The increasing emphasis on personalized medicine, supported by Korea's strong research infrastructure and the MFDS's regulatory framework for innovative medical devices, is driving innovation in custom Bioceramics implants and patient-specific surgical planning.

Policies

• MFDS Medical Device Registration and Medical Devices Act: All implantable Bioceramics medical devices must comply with the Medical Devices Act (MDA) and obtain appropriate regulatory approval from the Ministry of Food and Drug Safety (MFDS) before they can be manufactured, imported, marketed, or distributed in South Korea. Medical devices are classified into four risk categories (Class I to IV), with implantable devices typically classified as Class III or IV, requiring the most rigorous scientific review. For Class II, III, and IV devices, manufacturers must submit a technical dossier that proves the safety and effectiveness of the product.
• Korean Good Manufacturing Practice (KGMP) Certification: Unlike some jurisdictions that rely primarily on ISO 13485 certification, Korea requires formal KGMP certification issued under MFDS supervision. For implantable and higher-class devices, MFDS may conduct more detailed audits focusing on risk management integration within manufacturing controls.
• Korean License Holder (KLH) and Foreign Manufacturer Registration: Foreign manufacturers cannot directly submit device applications in Korea; they must complete Foreign Manufacturer Registration with the MFDS and appoint a Korean License Holder (KLH) or Designated MAH to represent them. All medical devices require pre-market registration from MFDS before they can be imported and placed on the Korean market.
• Post-Market Tracking and Implant Surveillance: A new legal framework for implantable devices has introduced post-market tracking requirements, reflecting South Korea's intent to encourage innovation while maintaining strict oversight of safety and quality. The MFDS requires manufacturers to submit technical documentation covering safety, performance, biocompatibility, and electromagnetic compatibility.
• NHIS Reimbursement Framework and Dental Coverage: The National Health Insurance Service (NHIS) provides universal health coverage to approximately 97% of the Korean population. The NHIS has progressively expanded coverage for dental services, with dentures added in 2012 and dental implants added in 2014 for older adults, with age eligibility gradually lowered to 65 years. The NHIS reimbursement framework for joint replacement procedures influences hospital procurement decisions for Bioceramics implants.
• Clinical Practice Guidelines and Specialty Society Standards: Utilization of Bioceramics devices in South Korea is aligned with evidence-based recommendations promoted by national professional organizations including the Korean Orthopaedic Association (KOA), which publishes the Journal of the Korean Orthopaedic Association, and the Korean Academy of Oral and Maxillofacial Implantology. The KOA's annual congress serves as a platform for presenting research on ceramic prostheses and implant outcomes.

Segment Analysis

South Korea Bioceramics Market By Type
• Bioinert Ceramics represents the largest product category in South Korea, driven by the country's exceptionally high adoption rate of ceramic bearings in hip replacements and the growing dental implant market. Registry data shows that ceramic-on-ceramic bearings are used at an overwhelmingly high rate (81%) in Korea compared to other countries. Bioinert ceramics maintain their physical integrity in the body and are ideal for load-bearing applications. Alumina and zirconia femoral heads are critical components in hip replacements, with ceramic implants offering superior wear resistance and longevity compared to metal alternatives. The growing number of arthroplasties total knee replacement surgeries rose from 64,515 in 2010 to 106,149 in 2024 drives demand for durable bioinert ceramic components. In dental applications, bioinert zirconia is increasingly preferred for implants and restorations. Meta Biomed Co., Ltd. manufactures Bioceramics root canal sealers. The Korean dental implant market is supported by NHIS coverage for older adults.
• Bioactive Ceramics maintains an important position in South Korea, particularly in applications requiring bone bonding, including hydroxyapatite coatings and bioactive glass. Himed and I&H Global have been advancing bioceramics in Korea for 15 years, raising awareness about the benefits of biomaterials like hydroxyapatite in medical implants. Sukgyung AT manufactures ultra-fine hydroxyapatite for orthopedic and dental applications. Calpore®, a novel biphasic artificial bone substitute composed of 60% beta-tricalcium phosphate and 40% hydroxyapatite, is produced by KYUNGWON MEDICAL CO., LTD. Bioactive ceramics are used to promote osseointegration in both orthopedic and dental surgeries.
• Bioresorbable Ceramics represents a growing segment in South Korea, driven by increasing demand for temporary implants, bone void fillers, and drug delivery systems. Inobone Co., Ltd. specializes in the manufacturing of bone substitutes for medical use, offering frabone and bioceramics powder products. These materials gradually dissolve and are replaced by natural bone, making them valuable in applications where permanent implants are unnecessary. The increasing number of trauma cases and the growing demand for bone regeneration solutions drive demand for bioresorbable ceramic materials.

South Korea Bioceramics Market By Material
• Zirconia represents a leading material category in South Korea, driven by the country's position as a global manufacturing powerhouse for dental implants and the growing demand for aesthetic dental restorations. Hass Bio specializes in the development and supply of all-ceramic dental materials, offering hybrid ceramics for enhanced aesthetics and strength. Zirconia's superior fracture toughness and aesthetic translucency make it the preferred material for dental implants and restorations. The Korean dental implant market is supported by robust domestic manufacturing, with dental implants representing the highest production performance at ₩2.81 trillion in 2024. The growing emphasis on aesthetics in dental care and the expanding NHIS coverage for older adults are driving zirconia adoption.
• Alumina maintains an important position in Korean orthopedics, with alumina ceramic heads widely used in hip replacements. The registry data shows that ceramic bearings are used at an overwhelmingly high rate (81%) in Korea. Alumina's high hardness and wear resistance make it suitable for load-bearing orthopedic applications. The high volume of hip replacements and the country's position as a leader in ceramic bearing adoption support consistent demand for alumina components.
• Calcium Phosphate is a critical material category encompassing hydroxyapatite and β-tricalcium phosphate for bone graft substitutes and implant coatings. Himed and I&H Global have been advancing bioceramics in Korea for 15 years. Sukgyung AT manufactures ultra-fine hydroxyapatite. KYUNGWON MEDICAL produces Calpore®, a biphasic artificial bone substitute composed of 60% β-TCP and 40% HA. The high prevalence of osteoarthritis and the growing volume of joint replacement procedures drive demand for calcium phosphate-based bone graft materials.
• Calcium Sulfate holds a niche position in the Korean market, primarily used as a synthetic bone void filler and antibiotic-eluting carrier for the treatment of osteomyelitis and infected surgical sites.
• Others (Carbon-based Ceramic, Bioactive Glass) includes carbon-based ceramics for cardiovascular applications, bioactive glass for bone regeneration, and emerging Bioceramics materials. Korean research institutions continue to explore novel Bioceramics materials. Biocera Co., Ltd. is a company specializing in ceramic applications.

South Korea Bioceramics Market By Application
• Orthopedics represents the largest application segment in South Korea, driven by the substantial burden of osteoarthritis and the growing volume of joint replacement procedures. Total knee replacement surgeries rose from 64,515 in 2010 to 106,149 in 2024. The number and rate of patients who underwent hip joint arthroplasty per 10,000 persons have been steadily increasing since 2007. Approximately 4.3 million people sought medical treatment for osteoarthritis in 2023. Orthopedic applications include ceramic femoral heads, ceramic knee components, calcium phosphate bone grafts, and hydroxyapatite coatings. The exceptionally high adoption rate of ceramic-on-ceramic bearings (81%) in Korean hip replacements drives substantial demand for Bioceramics components.
• Dental represents a significant and rapidly growing application segment, driven by Korea's position as a global manufacturing powerhouse for dental implants. Dental implants represented the highest production performance at ₩2.81 trillion in 2024, with an average annual growth rate of 19.7% over the past five years. Dental implant exports are expected to reach $1.003 billion in 2025. The NHIS has covered dental implants for older adults since 2014, with age eligibility gradually lowered to 65 years. Zirconia has emerged as the preferred material for implants, crowns, and bridges.
• Biomedical & Others encompasses tissue engineering scaffolds, drug delivery systems, cardiovascular applications, and surgical instruments. Inobone Co., Ltd. specializes in bone substitutes for medical use. Korean research institutions continue to investigate novel Bioceramics materials for emerging biomedical applications.

Major Bioceramics Manufacturers Operating in South Korea
• Meta Biomed Co., Ltd., founded in 1990 and headquartered in Cheongju-si, engages in the research, development, and production of dental and surgical materials, including Bioceramics root canal sealers.
• Inobone Co., Ltd., headquartered in Chungcheongnam-do, specializes in the manufacturing of bone substitutes for medical use, offering frabone and bioceramics powder products.
• Biocera Co., Ltd., headquartered in Gyeonggi-do, is a company specializing in ceramic applications.
• Hass Bio specializes in the development and supply of all-ceramic dental materials, offering CAD/CAM systems for dental restorations, lithium disilicate blocks and ingots, and hybrid ceramics for enhanced aesthetics and strength.
• Sukgyung AT manufactures ultra-fine hydroxyapatite for orthopedic and dental applications.
• KYUNGWON MEDICAL CO., LTD. produces Calpore®, a novel biphasic artificial bone substitute.
• Himed and I&H Global have been advancing bioceramics in Korea for 15 years, introducing hydroxyapatite biomaterials to Korean dental and orthopedic implant manufacturers.
• International players with significant presence include CeramTec, Zimmer Biomet, Stryker, DePuy Synthes, Smith & Nephew, Straumann, and Dentsply Sirona. The Korea International Medical & Hospital Equipment Show (KIMES) in Seoul serves as the largest medical device exhibition in Korea.

South Korea Bioceramics Procedure Economics
• Bioceramics implantation in South Korea operates within the NHIS universal health insurance framework, which provides comprehensive coverage for joint replacement procedures. The NHIS covers approximately 97% of the Korean population, with the remaining 3% covered by Medical Aid programs.
• In private hospitals and specialized orthopedic centers, the total cost of joint replacement surgery including the ceramic component, hospital charges, surgeon fees, and post-operative management varies depending on hospital category, implant type, and geographic location. The choice of bearing surface material ceramic-on-ceramic, ceramic-on-polyethylene, or metal-on-polyethylene significantly influences the cost and longevity of the implant. The exceptionally high adoption of ceramic-on-ceramic bearings (81%) in Korea reflects clinical preference for premium ceramic technologies despite their higher cost.
• In the dental sector, the NHIS has provided coverage for dental implants for older adults since 2014, with age eligibility gradually lowered to 65 years. The cost of dental implants varies depending on the material, manufacturer, and clinic location. The robust domestic manufacturing of dental implants in Korea, with production of ₩2.81 trillion in 2024, supports competitive pricing.
• Revision surgeries represent a significant economic burden. Between 2011 and 2019, the total cost of RTKA-f-PJI increased from $15.7 million to $19.6 million. The mean personal cost of RTKA-f-PJI was more than 4 times higher than that of RTKA-f-non-PJI. Revision surgeries are typically more complex, costly, and carry higher risks compared to primary procedures.

South Korea Bioceramics Market By End User
• Hospitals and Surgical Centers dominate Bioceramics utilization in South Korea. Total knee replacement surgeries rose from 64,515 in 2010 to 106,149 in 2024. The number and rate of patients who underwent hip joint arthroplasty per 10,000 persons have been steadily increasing since 2007. The Korean National Registry, managed through the HIRA database and NHIS, collects comprehensive data on joint replacement procedures. Robotic artificial joint surgery is gaining traction in Korean hospitals.
• Dental Clinics and Laboratories represent a significant end-user category, driven by Korea's position as a global manufacturing powerhouse for dental implants and the NHIS coverage for older adults. Dental implants represented the highest production performance at ₩2.81 trillion in 2024. Dental clinics provide patient-facing implant and restorative services, while dental laboratories manufacture crowns, bridges, and custom abutments using CAD/CAM technology.
• Others includes medical device manufacturers (OEMs), academic research institutions, and biotechnology companies. Meta Biomed, Inobone, Biocera, and Hass Bio represent domestic manufacturing capability in bioceramics and dental materials. Korean research institutions continue to advance Bioceramics research and development, supported by government agencies such as the Korea Health Industry Development Institute (KHIDI).

South Korea Bioceramics Market By Form
• Liquid (Injectable) & Others represents a growing form segment in South Korea, driven by the increasing adoption of ready-to-use formulations including injectable bone cements, premixed calcium phosphate pastes, flowable bone graft putties, and pre-sintered dental blocks for CAD/CAM milling. Hass Bio offers CAD/CAM systems for dental restorations. The adoption of digital dentistry technologies supports demand for pre-sintered zirconia blocks and other ready-to-use forms.
• Powder maintains an important position as raw material feedstock for OEM manufacturing, plasma-spray coating of metallic implants, and on-site mixing for bone graft applications. Inobone Co., Ltd. offers bioceramics powder products. Sukgyung AT manufactures ultra-fine hydroxyapatite powder. South Korea's robust domestic manufacturing of ceramic powders for dental and orthopedic applications reduces dependence on imports and supports the country's position as a net exporter of advanced ceramic components. Dental implant exports are expected to reach $1.003 billion in 2025.

Market Outlook by Healthcare Spending and Infrastructure

• South Korea's bioceramics market growth is linked to the country's unprecedented demographic transition to a super-aged society and its comprehensive NHIS universal health coverage. Korea officially became a super-aged society in December 2024. Approximately 4.3 million people sought medical treatment for osteoarthritis in 2023. Total knee replacement surgeries rose from 64,515 in 2010 to 106,149 in 2024.
• The Korean National Registry, managed through the HIRA database and NHIS, provides comprehensive data on arthroplasty trends. The registry data shows that ceramic-on-ceramic bearings are used at an overwhelmingly high rate (81%) in Korea compared to other countries. This exceptionally high adoption rate creates a substantial and sustained market for Bioceramics components.
• The future growth opportunity for bioceramics in South Korea depends on continued investment in robotic-assisted surgery, digital dentistry, and domestic manufacturing capabilities. The MFDS's regulatory framework for innovative medical devices supports the development and commercialization of advanced Bioceramics technologies. The Korea International Medical & Hospital Equipment Show (KIMES) serves as a platform for showcasing advanced Bioceramics technologies.
• Korea's robust domestic manufacturing of dental implants, with production of ₩2.81 trillion in 2024 and exports expected to reach $1.003 billion in 2025, positions the country as a global leader in dental bioceramics. Professional organizations including the Korean Orthopaedic Association (KOA) and the Korean Academy of Oral and Maxillofacial Implantology continue to advance the field through clinical research, guideline development, and professional education. The Korea Health Industry Development Institute (KHIDI) continues to support research and development in medical devices and biomaterials, including bioceramics.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Bioceramics Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Type
• Bioinert Ceramics
• Bioactive Ceramics
• Bioresorbable Ceramics

By Material
• Alumina
• Zirconia
• Calcium Phosphate
• Calcium Sulfate
• Others (carbon-based ceramic, Bio activated Glass)

By Application
• Orthopedics
• Dental
• Biomedical & others

By End User
• Hospitals and Surgical Centers
• Dental Clinics and Laboratories
• Others

By Form
• Powder
• Liquid (Injectable) & Others